B+
Bull case
25%
Probability
Target price
$170.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
LDOS
LeidosANYSE / Commercial & Professional Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$152.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$118.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-05
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.9
Score
AI commentary
Recent company IR releases add positive, dated contract evidence, but the packet lacks quantified market-reaction attribution, post-print analyst revisions, social coverage, and other sentiment indicators. The deterministic prior remains negative, and the company-specific contract upside is not yet linked to disclosed revenue or margin timing. Monitoring remains preferable to aggressive positioning.
RankAlpha Sentiment Codex - 2026-09-05
Open full AI memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-08-04eventQ2 FY2026 beat and raised guidanceMedium impact
Leidos reported Q2 revenue of $4.6 billion, adjusted EPS of $3.26, operating cash flow of $793 million, and free cash flow of $761 million. Management enhanced full-year revenue, earnings, and cash guidance. [#SEC-8K-2026-08-04]
2026-09-02catalystRecent director open-market sellingMedium impact
Two directors reported open-market sales in August and September 2026. This is a sentiment risk only and does not provide evidence about operating performance. [#SEC-FORM4-2026-08-13] [#SEC-FORM4-2026-09-02]
2026-12-04catalystMargin and Managed Healthcare execution riskHigh impact
Adjusted EBITDA margin declined to 13.8% from 15.2% year over year, while net income margin declined to 7.8% from 9.2%. Stored Q2 call context also flags Managed Healthcare contract uncertainty and possible insourcing pressure. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-05 • Updated nightlySource: Internal modelMethodology